Multiparametric magnetic resonance imaging (MRI) provides an accurate anatomical assessment of the tumor and its local staging. Herein, we report a case of intermediate-risk prostatic adenocarcinoma, initially followed on active surveillance, which upgraded from Gleason 7 (3 + 4) to Gleason 8 (4 + 4) on transrectal ultrasound/MRI fusion biopsy after progression of MR spectroscopic findings and review of the role of multiparametric MRI in the follow-up of patients with prostate cancer undergoing active surveillance.
*From the Molecular Pharmacology Section, Medical Oncology Branch, and †Molecular Imaging Program, National Cancer Institute, Bethesda, MD; ‡Urologic Oncology Branch, NCI, NIH, Bethesda, MD; §Center for Interventional Oncology, Radiology and Imaging Sciences CC, NIH, Bethesda, MD; ∥Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD; and ¶Laboratory of Pathology, NCI, NIH, Bethesda, MD.
Received for publication December 16, 2013; accepted January 2, 2014.
Reprints: Baris Turkbey, MD, Molecular Imaging Program, National Cancer Institute, 10 Center Dr, MSC 1182 Bldg 10, Room B3B69, Bethesda, MD 20892-1088 (e-mail: email@example.com).
Supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research, and the Center for Interventional Oncology.
The authors declare no conflict of interest.